---
aliases: [Biotech, Biotechnology, Pharma, Pharmaceuticals, Biopharmaceuticals]
---
#sector #healthcare #biotech #pharma

# Biopharma

**Biopharma** — Drug discovery and development. $1.5T+ market. AI transforming R&D. GLP-1 reshaping obesity.

---

## Market overview

| Metric | Value |
|--------|-------|
| Global pharma market | **$1.5T+** |
| AI in pharma market | $1.9B (2025) → $16.5B (2034) |
| Biotech VC (2024) | $26B across 416 rounds |
| AI drug deals (2025) | 120 deals (23% of total since 2017) |

---

## Market segments

| Segment | Key players | Notes |
|---------|-------------|-------|
| **Big Pharma** | [[Pfizer]], [[Merck]], [[Eli Lilly]], [[AbbVie]], J&J | Patent cliffs, diversified |
| **GLP-1 leaders** | [[Novo Nordisk]], [[Eli Lilly]] | Obesity/diabetes dominance |
| **Large-cap biotech** | [[Amgen]], [[Gilead]], [[Regeneron]], [[Vertex]] | Innovation + cash flow |
| **AI drug discovery** | Recursion, Insilico, Isomorphic | Emerging category |
| **Medtech** | Medtronic, Abbott, Boston Scientific | Devices, diagnostics |

---

## Key themes (2025-2026)

### GLP-1 / Obesity drugs

| Company | Drug | 2025 Status |
|---------|------|-------------|
| **[[Novo Nordisk]]** | Ozempic, Wegovy | $33B semaglutide run-rate |
| **[[Eli Lilly]]** | Mounjaro, Zepbound | 58% of US GLP-1 scripts |
| [[Amgen]] | MariTide | Phase 3, monthly dosing |
| [[Pfizer]] | Danuglipron | Struggling |

**TAM:** $100B+ obesity market by 2030.

### Patent cliffs

| Company | Drug | Expiry | Revenue at risk |
|---------|------|--------|-----------------|
| [[Merck]] | Keytruda | 2028 | ~$25B |
| Bristol-Myers | Opdivo | 2028 | ~$10B |
| [[AbbVie]] | Humira | 2023 (lost) | Biosimilar erosion |

### AI drug discovery

| Deal | Partners | Value |
|------|----------|-------|
| Insilico | Sanofi | $1.2B |
| Isomorphic Labs | Novartis + Lilly | ~$3B |
| Monte Rosa | Novartis | $5.76B (Sep 2025) |
| Recursion + Exscientia | Merged | Combined AI platform |

**Trend:** 30% of new drugs discovered using AI by 2025. 60% of biopharma execs increasing AI investment.

---

## Business models

| Model | Margin | Risk profile |
|-------|--------|--------------|
| Big Pharma | 70%+ gross | Patent cliff exposure |
| Biotech | Variable | Binary clinical outcomes |
| Biosimilars | Lower (~50%) | Regulatory, pricing |
| CDMO | 30-40% | Capacity utilization |

---

## Sector KPIs

| Metric | Definition | Good / Target | Why it matters |
|--------|------------|---------------|----------------|
| **R&D Intensity** | R&D Expense / Revenue | **>15-20%** | Fueling the pipeline (Future growth) |
| **Gross Margin** | (Rev - COGS) / Rev | **>75-80%** | Funding R&D and marketing leverage |
| **Patent Life** | Years of exclusivity | **>8-10 years** | Cash flow durability (Patent Cliff risk) |
| **Peak Sales** | Max annual revenue potential | **>$1B** | "Blockbuster" threshold for needle-moving |
| **Clinical Success** | Phase 1 to Approval rate | **~10% (Ind. Avg)** | Risk assessment (Higher is better) |
| **EV/Peak Sales** | Valuation vs Potential | **3-5x** | Valuation for late-stage/commercial assets |

---

## M&A landscape (2025)

**Drivers:**
- Patent cliff anxiety
- AI capability acquisition
- Pipeline gaps
- China asset licensing

**Trends:**
- 120 AI drug discovery deals in 2025
- China as source of early-stage assets
- Bispecific antibodies popular
- Large pharma acquiring vs building

---

## Regulatory environment

| Agency | Role |
|--------|------|
| **FDA** | Drug approval, accelerated pathways |
| **EMA** | European approval |
| **CMS** | Medicare drug pricing (IRA) |
| **FTC** | M&A review |

**IRA impact:** Medicare negotiation for top drugs starting 2026.

---

## Investment themes

| Theme | Expression |
|-------|------------|
| GLP-1 dominance | [[Novo Nordisk]], [[Eli Lilly]] |
| Patent cliff plays | Avoid concentrated exposure |
| AI drug discovery | Recursion, partnerships |
| Biosimilar growth | [[Amgen]] biosimilar portfolio |
| Gene therapy | [[Vertex]], CRISPR collaborations |

---

## Key risks

| Risk | Impact |
|------|--------|
| Clinical trial failures | Binary outcomes |
| Patent expiry | Revenue cliffs |
| Pricing regulation | IRA, global pressure |
| Competition | GLP-1 crowding |
| Geopolitical | China IP, tariffs |

---

## Related

- [[Healthcare]] — broader sector
- [[Eli Lilly]] — GLP-1 leader
- [[Novo Nordisk]] — GLP-1 leader
- [[Amgen]] — large-cap biotech
- [[Vertex]] — gene therapy pioneer
- [[Moderna]] — mRNA platform

---

## Sources

- [McKinsey: Biopharma dealmaking 2025](https://www.mckinsey.com/industries/life-sciences/our-insights/the-synthesis/pulse-check-key-trends-shaping-biopharma-dealmaking-in-2025)
- [Nature: Biotech deals 2025](https://www.nature.com/articles/d43747-025-00113-2)
- [VanEck: AI in biotech](https://www.vaneck.com/us/en/blogs/thematic-investing/ai-in-biotech/)

*Created 2026-01-09*
